ArticleBMC ophthalmology2025
Alterations in ganglion cell and nerve fiber layer in Leber hereditary optic neuropathy across clinical stages.
Article in BMC ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Cell-intrinsic vulnerability and immune activation cooperate to drive degeneration in a mitochondrial complex I deficiency model of optic neuropathy.Journal of neuroinflammation · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeLHON leads to gradual, painless, and permanent vision loss in both eyes, often associated with central scotomas. As the condition progresses, there is a decline in visual function, accompanied by noticeable structural alterations. This study focused on evaluating the clinical characteristics of patients with differing LHON stages, with a specific emphasis on optical coherence tomography (OCT) imaging results.
methodsThis analysis included 22 individuals with LHON. Patients underwent thorough clinical ophthalmologic assessments, including SD-OCT, Visual evoked potentials, and perimetry. When LHON was suspected, blood samples were obtained to test for the three major mitochondrial mutations (G1178A, T14484C, G3460A), with further sequencing to identify additional known mutations. The data were subsequently examined through descriptive statistical methods.
resultsThe clinical characteristics of 22 individuals (median age 33, range 9-68) were examined. All participants carried a mutation linked to LHON. The most prevalent mutation was G11778A (55%), followed by G3460A (23%), T14484C (14%), with one instance each of the rare G13042A and C3461T mutations. Fourteen participants experienced acute vision loss (average duration: 5.2 ± 5 months), while eight had chronic LHON. There was no significant difference in visual acuity (VA, logMAR) between the two groups (0.9 vs. 0.9, p = 0.91). However, chronic patients exhibited significantly reduced the retinal nerve fiber layer (RNFL), especially in the temporal region (32 μm vs. 56 μm, p < 0.0001), but not in the nasal region. Ganglion cell layer (GCL) thickness was also notably thinner in the temporal area for chronic patients compared to those with acute LHON (22 μm vs. 28 μm, p = 0.04). Linear regression analysis showed correlations between RNFL and GCL and visual acuity (R² = 0.18, p = 0.007 and R² = 0.1, p = 0.05).
conclusionIn our analysis, we observed an unusual pattern in the genetic mutations, with G3460A being the second most frequent, rather than T14484C, which may be attributed to the limited sample size. 14 patients experienced acute or subacute vision loss, while eight were assessed for chronic disease. Those with chronic LHON demonstrated significantly thinner GCL and RNFL. These results underscore the importance of accelerating both diagnosis and treatment to facilitate prompt intervention for patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.